Mifepristone

References Asch RH, Weckstein LN, Ralmaceda JP, Rojas F, Spitz JM, et al. Non-surgical expulsion of non-viable early pregnancy: a new application of RU 486. Human Reproduction 5: 481–483, 1990 Aubeny E, Baulieu EE. Contragestive activity of RU 486 and oral active prostaglandin combination. Comptes Rendus de L’Academie des Science 312: 539–45, 1991 Birth Control Trust. The Abortion Pill: Widening the choice for women. The Birth Control Trust, London, 1990 Brogden RN, Goa KL, Faulds D. Mifepristone. A review of its pharmcodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 44, in press, 1992 Cabrol D, Dubois C, Cronje H, Gonnet JM, Guillot M, et al. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. American Journal of Obstetrics and Gynaecology 163: 540–542, 1990 Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertility and Sterility 45: 5–17, 1986 Cook RJ. Antiprogestin drugs: medical and legal issues. Family Planning Perspectives 21: 267–272, 1989 Couzinet B, le Strat N, Silvestre L, Schaison G. Late luteal administration of the antiprogesterone RU 486 in normal women: effects on the menstrual cycle events and fertility control in a long-term study. Fertility and Sterility 54: 1039–1044, 1990 Crowley WF. Progesterone antagonism. New England Journal of Medicine 315: 1607–1608, 1986 Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy luteectomy evidence. Obstetrical and Gynaecological Survey 33: 69–81, 1978 Dubois C, Ulmann A, Baulieu EE. Contragestion with late luteal administration of RU 486 (Mifepristone). Fertility and Sterility 50: 593–596, 1988 Editorial. Mifepristone: widening the choice for women. Lancet 2: 1112–1113, 1989 Editorial. A death associated with mifepristone/sulprostone. Lancet 337: 969–970, 1991 Frank PI, McNamee R, Hannaford PC, Kay CR, Hirsch S. The effect of induced abortion on subsequent pregnancy outcome. British Journal of Obstetrics and Gynaecology 98: 1015–1024, 1991 Frydman R, Taylor S, Ulmann A. Transplacental passage of mifepristone. Lancet 2: 1252, 1985 Frydman R, Fernandez H, Pons JC, Ulmann A. Mifepristone (RU486) and therapeutic late pregnancy termination: a double-blind study of two different doses. Human Reproduction 3: 803–806, 1988 Frydman R, Baton C, Lelaidier C, Vial M, Bourget PH, et al. Mifepristone for induction of labour. Lancet 337: 488–489, 1991 Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Postcoital contraception with mifepristone. Lancet 337: 1414–1415, 1991 Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. Journal of Neurosurgery 74: 861–866, 1991 Gupta JK, Johnson N. Effect of mifepristone on dilation of the pregnant and nonpregnant cervix. Lancet 335: 1238–1240, 1990 Halbreich U. Treatment of premenstrual syndromes with progesterone antagonists (eg RU 486): political and methodological issues. Psychiatry 53: 407–409, 1990 Hardy RP, New DAT. Effects of the anti-progestin RU 38486 on rat embryos growing in culture. Food and Chemical Toxicology 29: 361–362, 1991 Heard M, Guillebaud J. Medical abortion. British Medical Journal 304: 195–196, 1992 Hempel S. No easy option. Nursing Times 87: 20–21, 1991 Henshaw RC, Templeton AA. Pre-operative cervical preparation before first trimester vacuum aspiration: a randomised controlled comparison between gemeprost and mifepristone (RU 436). British Journal of Obstetrics and Gynaecology 98: 1025–1030, 1991 Henshaw RC, Templeton AA, Naji SA, Russell IT. Medical abortion. Correspondence. British Medical Journal 304: 914, 1992 Hill NCW, Ferguson J, MacKenzie IZ. The efficacy of oral Mifepristone (RU 38,486) with a prostaglandin E1 analog vaginal pessary for the termination of early pregnancy: complications and patient acceptability. American Journal of Obstetrics and Gynecology 162: 414–417, 1990 Hull MGR, Gordon C, Beard RW. The organisation and results of a pregnancy termination service in a national health service hospital. The Journal of Obstetrics and Gynaecology of the British Commonwealth 81: 577–587, 1974 Joint Study of the Royal College of General Practitioners and the Royal College of Obstetricians and Gynaecologists. Induced abortion operations and their early sequelae. Journal of the Royal College of General Practitioners 35: 175–180, 1985 Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, et al. Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis. Fertility and Sterility 56: 402–407, 1991 Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Research 49: 2851–2856, 1989 Kovacs L. Future direction of abortion technology. In Bygdeman M (Ed.) Medical induction of abortion. Bailliere’s Clinical Obstetrics and Gynaecology, Vol. 4, 407–414, Balliere Tindall, London, 1990 Lim BH, Lees, DAR, Bjornsson S, Lunan CB, Cohn MR, et al. Normal development after exposure to mifepristone in early pregnancy. Lancet 336: 257–258, 1990 Loraine JA. Abortion: world perspectives in the mid-1980s. Family Practice 3: 266–271. 1986 Luukkainen T, Heinkinheimo O, Haukkamaa M, Lahteenmaki P. Inhibition of folliculogenesis and ovulation by the antiprogsterone RU 486. Fertility and Sterility 49: 961–963, 1988 Mahler H. The safe motherhood initiative: a call to action. Lancet: 668-670, 1987 Munday D, Francome C, Savage W. Twenty one years of legal abortion. British Medical Journal 298: 1231–1234, 1989 Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, et al. Successful treatment of Cushing’s Syndrome with the glucorticoid antagonist RU 486. Journal of Clinical Endocrinology and Metabolism 61: 536–540, 1985 Obel EB. Fertility following legally induced abortion. Acta Obstetrica Gynecologia Scandanavia 58: 539–542, 1979 Pons JC, Imbert MC, Elefant E, Roux C, Herschkorn P, et al. Development after exposure to mifepristone in early pregnancy. Lancet 338: 763, 1991 Report on Confidential Enquiries into Maternal Deaths in the UK 1985–1987. HMSO, London 1991 Rodger MW, Baird DT. Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. British Journal of Obstetrics and Gynaecology 97: 41–45, 1990 Schulz KF, Grimes DA, Cates W. Measures to prevent cervical injury during suction curettage abortion. Lancet 1: 1182–1185, 1983 Silvestre L, Dubois C, Renault M, Rezvani Y, Baulieu EE, et al. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. New England Journal of Medicine 322: 645–648, 1990 Stuenkel CA, Garzo VG, Morris S, Liu JH, Yen SS. Effects of the antiprogesterone RU 486 in the early follicular phase of the menstrual cycle. Fertility and Sterility 53: 642–646, 1990 Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. British Journal of Obstetrics and Gynaecology 95: 126–134, 1988 UK Multicentre Trial. The efficacy and tolerence of mifepristone and prostaglandin in first trimester termination of pregnancy. British Journal of Obstetrics and Gynaecology 97: 480–486, 1990 Urquhart DR, Templeton AA. Psychiatric morbidity and acceptability following medical and surgical methods of induced abortion. British Journal of Obstetrics and Gynaecology 98: 396–399, 1991 Urquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Human Reproduction 5: 883–886, 1990 Wolf JP, Chillik CF, Dubois C, Ulmann A, Raulieu EE, et al. Tolerence of perinidatory primate embryos to RU 486 exposure in vitro and in vivo. Contraception 41: 85–92, 1990 World Health Organization. Induced abortion. Technical report series, No. 623, World Health Organization, Geneva, 1978 Ylikorkala O, Alfthan H, Kaariainen M, Rapeli T, Lahteenmaki P. Outpatient therapeutic abortion with mifepristone. Obstetrics and Gynecology 74: 653–657, 1989 Author information Authors and Affiliations Rights and permissions About this article Cite this article Henshaw, R.C., Templeton, A.A. Mifepristone. Drugs 44, 531–536 (1992). https://doi.org/10.2165/00003495-199244040-00001 Published: Issue date: DOI: https://doi.org/10.2165/00003495-199244040-00001